<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04916093</url>
  </required_header>
  <id_info>
    <org_study_id>MinyaU</org_study_id>
    <nct_id>NCT04916093</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Antidiabetic Drugs in Recently Diagnosed Patients With Type 2 Diabetes</brief_title>
  <official_title>Safety and Efficacy of Sitagliptin, Vildagliptin, and Metformin in Recently Diagnosed Drug-naïve Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beni-Suef University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Minia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Beni-Suef University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study aims to investigate Sitagliptin and vildagliptin efficacy and safety&#xD;
      compared to metformin as 1st line options for T2D patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized case-controlled study in which drug-naive type-2 diabetic patients were&#xD;
      divided into 3 groups and followed up for three months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 20, 2019</start_date>
  <completion_date type="Actual">December 15, 2020</completion_date>
  <primary_completion_date type="Actual">June 10, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in glycemic parameters</measure>
    <time_frame>3-months</time_frame>
    <description>serum fasting glucose (mg/dl), and 2-hr postprandial glucose (mg/dl)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in Serum insulin (IU/l)</measure>
    <time_frame>3-months</time_frame>
    <description>using enzyme immunoassay (EIA) kits</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin resistance</measure>
    <time_frame>3-months</time_frame>
    <description>measured by HOMA model assessment (HOMA-IR) using the following formula: (Fasting insulin (IU/ml) × Fasting glucose (mg/dl))/405</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Beta cell function (HOMA-B)</measure>
    <time_frame>3-months</time_frame>
    <description>measured by (360 ×Fasting Insulin (IU/ ml) )/(Fasting glucose(mg/dl)-63)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in HbA1c (%)</measure>
    <time_frame>3-months</time_frame>
    <description>Changes in HbA1c (%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Lipid profile</measure>
    <time_frame>3-months</time_frame>
    <description>(total cholesterol, TG, HDL, and LDL) (mg/dl)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in liver enzymes</measure>
    <time_frame>3-months</time_frame>
    <description>ALT and AST (U/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Renal function tests</measure>
    <time_frame>3-months</time_frame>
    <description>creatinine and urea (mg/dl)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Sitagliptin Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Included 20 recently diagnosed type 2 diabetic subjects. They all received sitagliptin 100 mg therapy once daily before breakfast.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vildagliptin Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Included 20 recently diagnosed type 2 diabetic subjects. They all received vildagliptin 50 mg therapy twice daily before breakfast and supper.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Included 20 recently diagnosed type 2 diabetic subjects. They all received control 1 gm twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vildagliptin 50 MG</intervention_name>
    <description>Galvus 50 mg oral tablets</description>
    <arm_group_label>Vildagliptin Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin 100mg</intervention_name>
    <description>Januvia 100mg oral tablets</description>
    <arm_group_label>Sitagliptin Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MetFORMIN 1000 Mg Oral Tablet</intervention_name>
    <description>Glucophage 1000 mg oral tablets</description>
    <arm_group_label>Metformin Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Recently diagnosed type2 diabetic adult subjects who were not on an oral hypoglycemic&#xD;
             drug (OHA) at the screening visit were eligible to participate.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Type1 diabetes or ketoacidosis&#xD;
&#xD;
          2. End-organ failure as chronic renal failure (estimated serum creatinine level ≥&#xD;
             1.5mg/dl in male and ≥ 1.4mg/dl in female)&#xD;
&#xD;
          3. Liver cell failure (elevated alanine transaminase (ALT ) and/or aspartate transaminase&#xD;
             (AST) ≥ 2 folds)&#xD;
&#xD;
          4. Any stage of heart failure&#xD;
&#xD;
          5. Previous history of pancreatitis&#xD;
&#xD;
          6. Previous history of taking medication which may alter the efficacy of either drug eg:&#xD;
             (other OHA drug, corticosteroids, and oral contraceptives)&#xD;
&#xD;
          7. Pregnant or lactating females&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Asmaa A Elsayed, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>BUC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Minya University Hospital</name>
      <address>
        <city>Minya</city>
        <zip>61118</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>May 24, 2021</study_first_submitted>
  <study_first_submitted_qc>June 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2021</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beni-Suef University</investigator_affiliation>
    <investigator_full_name>Asmaa Abdelfattah Elsayed</investigator_full_name>
    <investigator_title>PHD candidate in clinical pharmacy department and PI</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Sitagliptin Phosphate</mesh_term>
    <mesh_term>Vildagliptin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

